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Abstract
Local recurrence is a common cause of treatment failure for patients with solid tumors. 
Intraoperative detection of microscopic residual cancer in the tumor bed could be used to decrease 
the risk of a positive surgical margin, reduce rates of reexcision, and tailor adjuvant therapy. We 
used a protease-activated fluorescent imaging probe, LUM015, to detect cancer in vivo in a mouse 
model of soft tissue sarcoma (STS) and ex vivo in a first-in-human phase 1 clinical trial. In mice, 
intravenous injection of LUM015 labeled tumor cells, and residual fluorescence within the tumor 
bed predicted local recurrence. In 15 patients with STS or breast cancer, intravenous injection of 
LUM015 before surgery was well tolerated. Imaging of resected human tissues showed that 
fluorescence from tumor was significantly higher than fluorescence from normal tissues. LUM015 
biodistribution, pharmacokinetic profiles, and metabolism were similar in mouse and human 
subjects. Tissue concentrations of LUM015 and its metabolites, including fluorescently labeled 
lysine, demonstrated that LUM015 is selectively distributed to tumors where it is activated by 
proteases. Experiments in mice with a constitutively active PEGylated fluorescent imaging probe 
support a model where tumor-selective probe distribution is a determinant of increased 
fluorescence in cancer. These co-clinical studies suggest that the tumor specificity of protease-
activated imaging probes, such as LUM015, is dependent on both biodistribution and enzyme 
activity. Our first-in-human data support future clinical trials of LUM015 and other protease-
sensitive probes.
INTRODUCTION
Surgical resection is the primary treatment modality for most solid tumors diagnosed before 
metastatic spread. In patients with soft tissue sarcoma (STS) of the extremity and breast 
cancer, organ-sparing surgery alone prevents local recurrence in about two-thirds of patients 
(1–3). Local recurrence is due to residual cancer in the tumor bed, the risk of which is 
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inferred by histopathological evaluation for the presence of tumor cells on the surface of the 
excised margin (1, 4). Intraoperative frozen margin assessment is limited by time and prone 
to sampling error, leading to false-negative results in up to 23% of cases (5). An 
intraoperative technique to accurately identify microscopic residual disease within the tumor 
bed could be used to decrease the risk of a positive surgical margin, reduce the rate of re-
resection, and tailor adjuvant therapy.
Emerging approaches to detect microscopic residual disease within the tumor bed include 
spectroscopy and optical imaging. Raman spectroscopy measures the scattering properties of 
tissues, and tumor-targeted Raman reporters like gold nanostars can provide excellent 
tumor-to-normal tissue contrast (6, 7). Fluorescence optical imaging resolves molecular 
features, and nonspecific fluorescent imaging probes such as methylene blue and 
indocyanine green provide contrast between tumor and normal tissues and are currently in 
clinical trials. The mean tumor-to-background ratio (TBR) with these imaging agents ranges 
from 1.2 to 8.5 in mouse and human studies (8–10). To increase the TBR, targeted (11–13) 
and activatable fluorescent probes have also been developed. Activatable probes are 
optically silent until cleaved by proteases that are overexpressed by tumors, such as 
cathepsin proteases (14–16). In a previous study, we used the LSL-KrasG12D/+; p53flox/flox 
(KP) and BrafCa/+; p53flox/flox (BP) mouse models of STS and a wide field-of-view imaging 
system to detect cathepsin-activated fluorescence in tumor cells (17). Residual fluorescence 
in the tumor bed correlated with local recurrence, and image-guided surgery improved 
outcomes for mice. This intraoperative imaging system has also been used in canine patients 
with spontaneous tumors (18).
Although protease-activated probes have shown promise preclinically, translation has been 
hindered by suboptimal preclinical models and limited funding for probe synthesis, toxicity 
studies, and phase 1 clinical trials. We were able to overcome these hurdles, among others, 
to translate protease-activated probes into the operating room. Here, we specifically 
explored the use of LUM015, a novel PEGylated protease-activated far-red fluorescent 
imaging probe. Preclinical toxicity studies of LUM015 were performed in rats and indicated 
a wide margin of safety. We report here a first-in-human phase 1 trial of LUM015 to test the 
safety of the probe in patients undergoing surgery for STS and breast cancer as well as 
LUM015 pharmacokinetics. Co-clinical studies in mice were conducted to optimize the dose 
and timing of LUM015 administration and to investigate the in vivo mechanisms of tumor 
specificity. Our studies support further clinical development of LUM015 in clinical trials 
with intraoperative imaging of the tumor bed.
RESULTS
LUM015 forms two different optically active metabolites
LUM015 consists of a commercially available fluorescence quencher molecule (QSY21) 
attached through a GGRK peptide to a 20-kD polyethylene glycol (PEG) and a Cy5 
fluorophore (Fig. 1A). LUM015 is optically inactive, but upon proteolytic cleavage by 
cathepsins K, L, and S (and, to some extent, B), the quencher is released (fragment 1) to 
create the optically active fragment 2 (Fig. 1B). Additional cleavage of LUM015 or 
fragment 2 yields the optically active fragment 3 (Fig. 1A). High-performance liquid 
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chromatography (HPLC) revealed distinct peaks for fragments 2 and 3 (Fig. 1C). The low-
level fluorescence detected from LUM015 itself is from ~1% Cy5 fluorescence not absorbed 
by the quencher. Patient plasma samples showed a strong peak corresponding to fragment 3 
as well as a smaller peak representing fragment 2 and uncleaved LUM015 (Fig. 1D), and 
human plasma profiles showed fragment 3 levels increasing during the first 8 hours after 
injection followed by clearance at a slower rate (Fig. 1E).
We then injected mice with and without primary STS tumors with LUM015 and measured 
[fragment 3]plasma over time after administration. At 1 hour, the concentration of fragment 3 
in plasma peaked in mice with tumors, but by 2 hours, plasma levels were similar to mice 
with no tumor, suggesting that fragment 3 was appreciably produced in nontumor tissues 
(Fig. 1F). In tumor tissue, most of LUM015 was metabolized, whereas in blood, muscle, 
liver, and kidney tissue, half or more of LUM015 remained uncleaved (fig. S1). In contrast 
to fragment 3 being the major metabolite after in vivo administration of LUM015 to 
patients, fragment 2 was the predominant cleavage product in vitro.
LUM015 fluorescently labels tumor cells in mice
To test the specificity of LUM015 for tumor cells, we administered LUM015 (3.5 mg/kg) 
via tail vein injection into 16 mice with primary STS in the lower extremity. This dose of 
LUM015 was chosen on the basis of preclinical studies performed with other protease-
activatable probes in the same mouse model (17). Six hours later, we resected the STS and 
normal muscle from the contralateral leg. Fluorescence imaging of the resected tissues 
revealed a mean tumor fluorescence that was nearly fivefold higher than that of muscle (Fig. 
2A). In a mouse model of breast cancer, LUM015 fluorescence was significantly greater in 
tumor than in muscle (Fig. 2B).
Because tumors consist of cancer and stromal cells, we next investigated to what extent 
LUM015 labeled these cells using mice with tumors that express yellow fluorescent protein 
(YFP). After 6 hours, tumors resected from mice injected with LUM015 had a significantly 
higher proportion of Cy5+ fluorescent cells compared to control animals given saline (Fig. 
2C). About 62% of the LUM015-labeled cells were YFP+ tumor cells, and less than 10% 
were CD11b+ tumor-associated monocytes and macrophages (Fig. 2C), indicating that most 
Cy5-labeled cells were tumor cells. Polymerase chain reaction (PCR) genotyping of 
genomic DNA from the Cy5+ cells that were YFP−/CD11b− revealed that most of these cells 
were tumor cells, which activated LUM015 but may have lost expression of the YFP 
marker, mixed together with some CD11b− stromal cells (fig. S2A). Conversely, in pure 
populations of YFP+/CD11b+ cells, the proportion of Cy5+ cells was higher in the tumor cell 
population than in the monocyte population, but the efficiency of labeling in tumor cells was 
about 20% in mice (fig. S2).
Having demonstrated that LUM015 fluorescently labels sarcoma cells, we next used an 
autochthonous mouse model of STS with marginal resection to determine if residual 
fluorescence in the tumor bed after surgical removal of the tumor predicted local recurrence. 
Residual fluorescence within the tumor bed was determined intraoperatively as fluorescence 
exceeding 80% of the minimum signal from the excised tumor (fig. S3) (17). After imaging 
the tumor bed, the surgical wound was closed, and the mice were monitored for local 
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recurrence–free survival. All mice positive for residual fluorescence at the time of surgery 
developed local recurrence of their tumors within 70 days of surgery. In comparison, only 
one-third of the mice without residual fluorescence in the tumor bed experienced local 
recurrence within 200 total days of follow-up (Fig. 2D).
LUM015 is safe in humans
After demonstrating that LUM015 selectively labeled sarcoma and breast cancer in mice, we 
performed a first-in-human phase 1 clinical trial of LUM015. This trial enrolled 15 patients, 
12 with STS and 3 with invasive ductal carcinoma (IDC) of the breast. Four of the 12 STS 
patients had undifferentiated pleomorphic sarcoma (UPS), and the other eight represented 
several different STS subtypes. The tumor subtypes, grade, size, and anatomic locations are 
described in Table 1. LUM015 was administered to six patients at a 0.5 mg/kg dose, six 
patients at a 1.0 mg/kg dose, and three patients at a 1.5 mg/kg dose, according to a modified 
3 + 3 design (NCT01626066). These human doses were chosen on the basis of the estimated 
effective dose of 3.5 mg/kg in mice, which often corresponds to a lower effective dose in 
humans owing to differences in the ratio of body surface area to body weight (19). Surgical 
removal of the tumors immediately followed by ex vivo fluorescence imaging of the 
resected specimens was done either the same day as probe injection (at ~6 hours) or the 
following day (at ~30 hours). Tissue samples imaged ex vivo were biopsied for subsequent 
histological analysis.
LUM015 was well tolerated by study subjects, and no adverse pharmacological activity or 
hypersensitivity reactions occurred during the study (table S1). All subjects experienced 
green chromaturia, which was expected based on the blue color of LUM015. Two sarcoma 
patients had wound healing complications, which is within the expected range for this 
patient population and not considered related to LUM015; both of these patients had 
received preoperative radiation therapy, which is known to delay wound healing in STS 
patients (20). Patient 11 experienced a minor transient elevation of liver function tests for 
aspartate aminotransferase at 59 U/liter (normal range, 15 to 41) and alanine transaminase at 
58 mg/dl (normal female range, 14 to 54) 8 hours after LUM015 administration, which was 
determined to be only possibly related to the investigational probe and therefore did not 
meet the criteria for adverse pharmacological activity, as defined by the clinical protocol 
(table S2). Notably, the tissue imaged for patient 10 did not include tumor, and therefore, 
this patient was excluded from tumor tissue analyses.
Co-clinical studies in mice and humans show similar pharmacokinetics
Blood samples were collected from mice and patients at regular intervals after intravenous 
administration of LUM015, and liquid chromatography–tandem mass spectrometry (LC-
MS/MS) was used to measure [LUM015]plasma at these time points. Summary 
pharmacokinetic parameters suggesting a linear dose response in humans are reported in fig. 
S4. Plasma clearance profiles for mice and humans injected with a 1.5 mg/kg dose of 
LUM015 were similar (Fig. 3A). Tumor fluorescence in the first six humans imaged at 30 
hours was lower than fluorescence measured in mice at 6 hours, but in both mice and 
humans, absolute tumor fluorescence was significantly higher when measured 6 hours after 
LUM015 administration compared to 30 hours (Fig. 3B). In contrast, we did not find a 
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significant effect of imaging time on the tumor-to-normal tissue fluorescence ratio (T/N) in 
humans or mice (Fig. 3C). Thus, the imaging time point was shortened to 6 hours after 
LUM015 administration for the remainder of the phase 1 trial. Furthermore, at 6 hours, the 
fluorescence ratio (tumor/normal) measured in humans administered the highest LUM015 
dose (1.5 mg/kg) was significantly higher than those measured in the two lower-dose 
cohorts (Fig. 3D).
LUM015 fluorescence is tumor-selective in STS and breast cancer patients
To determine if preoperative administration of LUM015 results in tumor-specific 
fluorescence, we compared the absolute fluorescence in the tumor with the absolute 
fluorescence in adjacent normal tissue from all patients (Table 1), except for patient 10. The 
presence or absence of cancer in the samples was confirmed by subsequent histological 
analysis by a pathologist blinded to the imaging data (table S3). Normal muscle, adipose, or 
breast tissue from the margin of tissue resected around the tumor was used for the normal 
tissue comparison unless otherwise noted in table S3. Three representative examples of ex 
vivo imaging from a patient with a high-grade UPS of the thigh, a patient with a high-grade 
myxofibrosarcoma of the thigh, and a patient with a high-grade IDC of the breast are shown 
(Fig. 4, A to C). UPS is the most common type of STS in the trial and is phenotypically 
most similar to the mouse model in our preclinical studies. Myxofibrosarcoma is locally 
aggressive, and complete resections are challenging; thus, these patients may particularly 
benefit from this intraoperative imaging technology.
For each patient, we imaged one to six tumor and normal tissue sites that were histologically 
confirmed, and the mean fluorescence value is reported. Overall, tumor fluorescence was 
significantly higher than matched normal tissue fluorescence with a mean tumor/normal 
fluorescence ratio of 4.1 (Fig. 4D). The tumor/normal fluorescence ratio was less than or 
equal to 1 in two of the patients, both of whom were imaged at the 30-hour imaging time 
point and had low-grade sarcomas (well-differentiated liposarcoma and myxoinflammatory 
fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor). Furthermore, we found that 
across all patients, the means of absolute tumor, muscle, and adipose fluorescence values 
were significantly different (Fig. 4E).
Biodistribution and protease activation contribute to tumor fluorescence
After determining that fragment 3—with Cy5, no PEG— was the major LUM015 metabolite 
in human plasma (Fig. 1), we measured the concentrations of both fragments and intact 
LUM015 in human tissues (table S4) and in a cohort of 18 mice injected with LUM015 (1.5 
mg/kg). At 6 hours, [fragment 3]tumor correlated significantly with tumor fluorescence in 
mice and in humans (Fig. 5A). A similar analysis of fragment 2 showed a weaker correlation 
with tissue fluorescence (Fig. 5A). To measure the contribution of proteolytic probe 
activation to tumor-selective fluorescence, we calculated the fraction of LUM015 and its 
metabolites that were present in the optically active state for each mouse sample. In the 
mouse cohort, sarcomas had a fraction of activated probe (FAP) of 0.38, which was about 
50% higher than normal muscle (Fig. 5B). In human tumor samples imaged at 6 hours, 
tumors had a FAP of 0.26, which was about 60% higher compared to normal tissues (Fig. 
5B), but this difference did not reach statistical significance, even at 30 hours.
Whitley et al. Page 6
Sci Transl Med. Author manuscript; available in PMC 2017 January 06.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
In the mouse STS cohort and the human STS patients imaged at 6 hours with normal muscle 
available for comparison (patients 8, 11, 12, 13, and 14; table S3), tumor/muscle 
fluorescence ratios were correlated with the corresponding activation ratio; however, this 
correlation was significant only for the mouse samples (Fig. 5C). In an analysis inclusive of 
all patients, there was a significant correlation between fluorescence and activation (fig. 
S5A). To measure the contribution of biodistribution to tumor-selective fluorescence, the 
total concentration of LUM015 and its cleavage products, [total probe (TP)], was 
determined for each sample. In both the mouse and human STS cohorts, sarcomas had a 
[TP] that was greater than normal muscle (Fig. 5D). Additionally, [TP] was higher in human 
tumors imaged at 6 hours when compared to tumors imaged at 30 hours (fig. S5B). 
Furthermore, we found that tissue fluorescence and [TP] had a significant positive 
correlation in the mouse cohort, the human STS cohort, and the overall human data set (Fig. 
5, E and F).
To image tumors with a probe that does not require protease activation, we injected STS-
bearing mice with either LUM015 or LUM033, a constitutively active fluorescent imaging 
probe identical to fragment 2 (also from Lumicell Inc.). Six hours after injection, resected 
tumors had a tumor/normal fluorescence ratio twofold higher for LUM015 than for 
LUM033 (Fig. 5G). Therefore, protease activation may serve to double the level of tumor-
to-normal contrast that is achieved by tumor-selective biodistribution alone. These findings 
suggest that tumor-selective distribution of LUM015 is a critical determinant of T/N, which 
is further enhanced by tumor-specific protease activation.
Because biodistribution is one of two major determinants of tumor-specific fluorescence 
measured after administration of LUM015, we used immunofluorescence and 
immunohistochemistry to further examine the distribution of LUM015 to tumor and normal 
tissues. As a control for immunofluorescence, we used formalin-fixed paraffin-embedded 
(FFPE) sections of tumor tissue from human sarcoma patients not injected with LUM015. 
Patients who had been injected with LUM015 showed a positive signal for PEG, whereas 
the control tissues did not (Fig. 6A). In a breast cancer sample from patient 15 that contained 
both areas of tumor and adjacent normal tissue, PEG signal localized to areas of tumor, with 
less intense staining in normal tissue (Fig. 6B). Areas adjacent to tumor containing a 
lymphocytic infiltrate were also negative for PEG staining. The amount of PEG staining was 
significantly less in normal muscle and breast tissues compared to sarcomas and breast 
cancer, respectively (Fig. 6, C and D). These results for PEG staining, together with the 
quantification of LUM015 and its metabolites, suggest that tumor-selective distribution of 
LUM015 may serve to delineate the tumor margin while protease activation intensifies the 
contrast between tumor and normal tissue types for intraoperative imaging.
DISCUSSION
There is an unmet need for a real-time method to determine the presence of microscopic 
residual cancer within the tumor bed at the time of surgery, which could reduce the need for 
re-resection, lower the rates of local recurrence, and personalize adjuvant therapy. A 
particularly attractive approach to detect residual disease is fluorescence imaging because it 
can be functionally and/or molecularly targeted and provide cellular resolution with 
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penetration depths of up to several millimeters (11). Protease-activated fluorescent imaging 
probes were first introduced more than 15 years ago to provide optical contrast between 
tumor and normal tissues (14, 21–23). Many of these probes have been tested in preclinical 
models. This is the first study to use these probes to image human cancers and investigate 
the relative importance of protease activation versus biodistribution for achieving tumor-to-
normal tissue contrast.
We show here that the PEGylated, protease-activated probe LUM015 specifically labels 
tumors in a mouse model of STS as well as in humans with STS and breast cancer. Flow 
cytometric studies of tumors from LUM015-injected mice showed that most fluorescently 
labeled cells were tumor cells, and less than 1/10 were tumor-associated monocytes and 
macrophages. The labeling of tumor-associated macrophages likely occurs because these 
cells also express high levels of proteases (24), and the intraoperative identification and 
removal of these cells may, in fact, be beneficial to patients because these cells are 
associated with tumor progression and metastasis (25, 26). In mice injected with LUM015, 
residual fluorescence within the tumor bed was highly predictive of local recurrence, 
suggesting that this intraoperative imaging system could be useful to guide surgery and 
tailor adjuvant therapy.
In a first-in-human phase 1 trial in patients undergoing surgical resection of STS or breast 
cancer, we found that LUM015 is safe and well-tolerated at a dose that allows for detection 
of tumor-specific fluorescence. We observed that the plasma clearance profile of LUM015 
in humans and mice is similar. On the basis of allometric scaling, we expected that the 
clearance rate would be significantly slower in humans (27, 28) so that a greater interval of 
time between LUM015 administration and tumor resection would be required to allow for 
optimal tumor-to-normal tissue contrast. Our results are consistent with the findings that 
standard allometric scaling does not accurately predict human pharmacokinetic parameters 
for PEGylated compounds (29). On the basis of this information, we modified the phase 1 
clinical trial to include imaging at the 6-hour time point, resulting in higher tumor 
fluorescence in human cancers than imaging at 30 hours.
Consistent with data from mice and dogs (18), when patients with STS or breast cancer were 
injected with LUM015 before surgery, we found tumor tissue fluorescence measured ex 
vivo to be significantly higher than fluorescence measured from adjacent normal tissues. It 
is important to note that this study included patients with both sarcoma and breast cancer, 
and that within these tumors, different subtypes were included. A T/N of greater than 1 was 
measured in 12 of 14 patients, indicating that LUM015 may be effective for fluorescent 
labeling of many different types of cancer. However, the human T/N reported in this study 
were measured in ex vivo bulk tissue, and future clinical trials with LUM015 with in vivo 
tumor bed imaging will be necessary to define a clinically meaningful T/N cutoff. 
Nevertheless, the in vivo tumor bed imaging in our mouse experiments suggests that 
LUM015 can provide a sufficient T/N for detecting residual cancer.
Tissue measurements of LUM015, PEG, and its metabolites showed that selective 
biodistribution in tumors was an important factor in tumor-selective imaging. Tumor-
specific protease activation serves to enhance the contrast that is established with differential 
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distribution, suggesting that by targeting the tumor through both mechanisms 
simultaneously, a larger tumor-to-normal contrast is achieved. However, in mice, we found 
that the generation of fragments in vivo did not require the presence of cancer and could be 
formed in isolated blood, muscle, liver, and kidney. This suggests that protease activation 
does not fully account for the tumor/normal ratio, and instead is established in part by 
tumor-selective accumulation through the enhanced permeability and retention effect.
This study shows that preoperative administration of LUM015 to patients with sarcoma or 
breast cancer results in tumor-specific fluorescence that can be detected upon ex vivo 
imaging of resected tissues. However, future clinical studies will be needed to measure 
fluorescence in vivo, specifically residual cancer cells at the tumor margins. We report in 
vivo imaging data from mice and show that intraoperative imaging with LUM015 predicts 
local recurrence with high specificity. However, some mice with negative residual 
fluorescence did develop local recurrence. Therefore, it will be necessary to optimize 
fluorescence thresholding methods to increase the sensitivity of the system while 
maintaining high specificity.
This work presents a first-in-human phase 1 clinical trial of an intravenously administered, 
protease-activated fluorescent intraoperative imaging probe. We have shown that LUM015 
is safe for use in humans and generates tumor-specific fluorescence. These studies support 
future clinical trials of LUM015 using intraoperative imaging of the tumor bed and 
comparing imaging results with histopathology. A feasibility study of intraoperative imaging 
with the LUM system has recently started for breast cancer patients (NCT02438358), but it 
may be possible to use the probe for patients with other cancers, such as sarcoma (as 
demonstrated in mice) and gastrointestinal cancers. Our co-clinical studies in mice and 
humans reveal that pharmacokinetic and pharmacodynamic parameters are conserved across 
species, which may aid in the translation of other preclinical imaging agents for human use.
MATERIALS AND METHODS
Co-clinical study design
In this co-clinical study, data regarding the pharmacokinetics, specificity, and mechanism of 
action of LUM015 were gathered in both mice and humans. Preclinical studies in the mice 
provided justification for a phase 1 clinical trial in humans. During the clinical trial, parallel 
mouse studies were conducted to further explore clinical observations regarding LUM015 
pharmacokinetics and the mechanism of tumor-selective fluorescence. The objective of the 
controlled laboratory experiments was to use a primary mouse model of STS and orthotopic 
models of breast cancer to investigate the in vivo activity of LUM015 and explore the 
mechanism of LUM015 distribution and activation in vivo.
All animal studies were performed in accordance with protocols approved by the Duke 
University and Massachusetts General Hospital Institutional Animal Care and Use 
Committees. Sample sizes were selected before initiating the study based on previous 
intraoperative imaging studies conducted in the laboratory (17), and power calculations were 
performed as described previously (30). Data collection was stopped if a smaller sample size 
achieved statistical significance. No outliers were excluded in this study. The mice in this 
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study were not randomized to their treatments and were selected on the basis of availability. 
The investigators were not blinded when performing tissue fluorescence measurements.
The primary objective of the single institution, open-label, nonrandomized phase 1 trial 
(NCT01626066) was to determine a safe and recommended dose of LUM015 that labels 
tumors. Secondary objectives included obtaining ex vivo imaging information of the tumor 
and any adjacent normal tissue as well as collecting pharmacokinetic/pharmacodynamic 
information. Patients with the diagnosis of STS or breast cancer scheduled for tumor 
resection were included. Patients treated with neoadjuvant radiation therapy were included 
in the study based on our previous data that radiation therapy does not alter the fluorescence 
from protease-activated imaging probes in a mouse model of STS (31). The sample size was 
determined on the basis of a modified 3 + 3 dose escalation design to provide information on 
the relationship between dose and fluorescence signal while observing patients for adverse 
pharmacological activity. No outliers were excluded in this study. Informed consent was 
obtained from each patient, and the study was approved by the Duke University School of 
Medicine and Copernicus Institutional Review Boards. The study was also run under an 
Investigational New Drug application filed with the U.S. Food and Drug Administration. A 
safety monitoring committee was formed to protect the rights, safety, and welfare of 
participants, and additional monitoring was done by the Duke Cancer Institute (DCI) Safety 
Oversight Committee.
Patients underwent standard operative and perioperative treatment. Resected patient tissues 
underwent standard surgical pathology procedures before being imaged and sampled for the 
study with the guidance of a clinical pathologist blinded to the fluorescence imaging 
measurements. Safety evaluations, described in Supplementary Materials and Methods, were 
conducted before and after peripheral intravenous administration of LUM015 at three 
predetermined doses: 0.5, 1.0, or 1.5 mg/kg. LUM015 was administered either the day 
before or on the morning of surgery. LUM015 was supplied free of charge from Lumicell 
Inc. Patient blood samples were collected before and after LUM015 administration for 
pharmacokinetic/pharmacodynamic studies.
Fluorescent agent administration and imaging
Mice were administered LUM015 or LUM033 via tail vein injection when tumors reached 
about 1000 mm3 (4 to 5 mm in diameter). Blood samples for pharmacokinetic studies were 
obtained from the submandibular vein. After a specified time interval, the animals were 
euthanized, and tissues were removed for fluorescence imaging and other analyses. For the 
local recurrence study, tumors were removed and intraoperative assessment of residual 
fluorescence was performed as described previously (17). The handheld LUM imaging 
device was described previously (17), and the specifications are provided in Supplementary 
Materials and Methods. Normal and tumor tissues were identified grossly, and the imaging 
tip was applied to the tissue to obtain two to three images of the same location. The tissue 
was biopsied at the site of imaging for identification of the tissue type by histological 
analysis (H&E) and measurement of LUM015 and its metabolites (fragment 2 and Cy5-
Lys).
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Image processing was performed using a custom script developed in the Matlab 
programming environment (MathWorks) using standard corrections for background and 
signal distribution (32), described in Supplementary Materials and Methods. Mean pixel 
intensities derived from the Matlab script are reported in this study. For visual representation 
of images, the contrast and brightness of images were adjusted as described previously (17) 
so that the reader can appreciate the differences in fluorescence intensities between tumor 
and normal tissue.
Histological analysis, immunohistochemistry, and immunofluorescence
FFPE sample tissues were sectioned to create 5-μm-thick slides for H&E staining, PEG 
immunohistochemistry, and immunofluorescence studies. Staining and quantification 
methods are described in Supplementary Materials and Methods. Slides were reviewed by a 
clinical pathologist specializing in STS (D.M.C.), who was blinded to tissue fluorescence 
measurements.
Flow cytometry
KPY mice harboring primary sarcomas were injected with either LUM015 (3.5 mg/kg) or 
PBS vehicle, and tumors were collected 6 hours after injection. Cells were dissociated from 
tumors according to methods described previously (33). Total cells dissociated from tumors 
were incubated with rat anti-mouse CD16/32 immunoglobulin G (IgG) (BD Pharmingen) 
and phycoerythrin-Cy5–conjugated anti-mouse CD11b IgG (eBioscience). Data were 
collected from at least 200,000 cells by FACSCanto (BD Pharmingen) and analyzed by 
FlowJo (Tree Star Inc.). Genomic PCR analysis to show recombination of the mutant Kras 
allele was performed with the following primers: (i) 5′-GTCTTTCCCCAGCACAGTGC-3′; 
(ii) 5′-CTCTTGCCTACGCCACCAGCTC-3′; (iii) 5′-
AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3′. The wild-type Kras allele yields a 
622-bp band, the unrecombined LSL-KrasG12D allele yields a 500-bp band, and the 
recombined 1-loxP-KrasG12D allele yields a 650-bp band.
Plasma and tissue metabolite measurements
Concentrations of LUM015 and its metabolites in plasma and tissue samples were 
determined using LC-MS/MS as well as HPLC with fluorescence detection (HPLC-FD). A 
detailed methodology is presented in Supplementary Materials and Methods.
Statistics
Results are presented as means ± SEM unless otherwise indicated. Before analysis, all data 
were displayed graphically to determine whether parametric or nonparametric tests should 
be used. Two-tailed Student’s t test was performed to compare the means of two groups, and 
a matched pair t test was used when comparing fluorescent measurements from the same 
patient. A Mann-Whitney test was performed to compare the means of two groups when 
data were distributed nonparametrically. Two-way ANOVA was performed to examine the 
interaction between two independent variables such as dose and imaging time, and one-way 
ANOVA was used when measuring the effect of only one variable, such as tissue type. 
These were followed by Bonferroni or Tukey’s post hoc multiple comparison tests for 
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pairwise comparisons of individual treatments or tissue types. For local recurrence studies, 
Kaplan-Meier analysis was performed with the log-rank test for statistical significance. To 
find the correlation of two different measurements from the same sample, we determined the 
Pearson coefficient (r) and r2. Significance was assumed at P < 0.05. All calculations were 
performed using Prism 6 (GraphPad).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Cy5-Lys is the major fluorescent LUM015 metabolite
(A) Expected LUM015 cleavage products: Fragment 1 contains the quencher QSY21, and 
optically active fragments 2 and 3 contain the Cy5 fluorophore. (B) In vitro protease (0.5 
μM) activation of LUM015 (5 μM). Fluorescence was measured at multiple time points with 
peak excitation at 650 nm and fluorescence emission collection at 675 nm (n = 6 replicates 
per enzyme). (C and D) HPLC analysis of pure LUM015 (25 ng/ml), fragment 2 (25 ng/ml), 
and fragment 3 (2.5 ng/ml) (C) and a representative patient plasma sample collected from 
patient 14 at 8 hours after intravenous administration of LUM015 (1.5 mg/kg) (D). (E and 
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F) Plasma profiles of fragment 3 in three patients (E) and in tumor-bearing and non–tumor-
bearing mice (n = 6 mice per group) (F) each injected with LUM015 (1.5 mg/kg). P value 
determined by unpaired t test.
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Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer
(A and B) Mean measured fluorescence in primary sarcoma (n = 16) (A) or orthotopic breast 
cancer (n = 23) (B) and muscle. P values determined by unpaired t test. Representative 
fluorescence images of resected normal muscle and tumors are shown along with 
corresponding hematoxylin and eosin (H&E) histology. The same contrast scale was applied 
to both fluorescence images in each pair. Scale bars, 5 mm for fluorescence images; 500 μm 
for H&E images in (A); 100 μm for H&E images in (B). (C) Representative flow cytometric 
analysis of resected mouse tumors expressing tumor cell–specific YFP after intravenous 
administration of phosphate-buffered saline (PBS) or LUM015 (3.5 mg/kg). Of the tumors 
from mice treated with LUM015, Cy5+ cells (red box, cells with fluorescence >2 × 102) and 
YFP+ tumor cells (yellow box) were sorted and quantified (nPBS = 2 mice, nLUM015 = 3 
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mice). In the Cy5+ cells, the proportions of YFP+ tumor cells and CD11b+ tumor–associated 
macrophages were further quantified (n = 3 mice). P values were determined by unpaired t 
test. (D) The correlation between residual fluorescence within the sarcoma tumor bed 
measured before wound closure and local recurrence–free survival in mice. P value 
determined by log-rank test.
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Fig. 3. Comparative LUM015 pharmacokinetics in mouse and human subjects
(A) LUM015 plasma clearance profile in mouse and human subjects administered a 1.5 
mg/kg dose of LUM015. [LUM015]plasma is given as a fraction of the maximum 
concentration and shown on a log scale. (B) Tumor fluorescence in patients and mice at the 
6- and 30-hour imaging time points (n = 5 mice and 3 humans per dose cohort). P = 0.02 for 
imaging time, as determined by two-way analysis of variance (ANOVA). (C) Tumor/normal 
fluorescence ratio in mice and humans at the 6- and 30-hour imaging time points. P = 0.6 for 
imaging time, as determined by two-way ANOVA. (D) Tumor/normal fluorescence ratio 
measured in humans and mice by dose (nmouse-1.5, 3.5 = 5; nhuman-0.5, 1.0 = 3; nhuman-1.5 = 2). 
P values for dose cohort comparisons determined by Tukey’s multiple comparisons test. P = 
0.02 for dose effect on human subset determined by one-way ANOVA.
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Fig. 4. Tumor-selective fluorescence in patients receiving intravenous LUM015 before resection
(A to C) Representative human subjects with UPS of the thigh (A, patient 2), 
myxofibrosarcoma of the thigh (B, patient 12), and IDC of the breast (C, patient 9). From 
left to right: gadolinium-enhanced magnetic resonance imaging, gross tissue resection 
containing tumor (T) and normal muscle (M), H&E histology of imaged tumor tissue, 
fluorescence image of tumor tissue obtained with the LUM device, H&E staining of imaged 
muscle, fluorescence image of muscle obtained with the LUM device. (D) Tumor tissue 
fluorescence and fluorescence measured from adjacent normal tissue in the same patient (n = 
14). P value determined by paired t test. (E) Distribution of tumor, muscle, and adipose 
tissue fluorescence across all patients (ntumor = 14, nmuscle = 10, nadipose = 11). P = 0.04 for 
tissue type effect determined by one-way ANOVA. P values for tumor to muscle and 
adipose comparison determined by unpaired t test.
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Fig. 5. Tumor-selective distribution and activation of LUM015
(A) Tumor fluorescence as a function of [fragment 3]tumor and [fragment 2]tumor (nhuman = 
14, nmouse = 16). P values determined by F test on the linear regression model. (B) The FAP 
was determined using the following equation: ([fragment 2 (nM)]tissue + [fragment 3 
(nM)]tissue)/([LUM015 (nM)]tissue + [fragment 2 (nM)]tissue + [fragment 3 (nM)]tissue). FAP 
data are shown for muscle and tumor tissue samples from human (n = 5, patients 8 and 11 to 
14) and mouse (n = 18) STS subjects and from all human subjects imaged at 6 and 30 hours 
(n = 14). P values determined by unpaired t test. (C) Correlation between the tumor: muscle 
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fluorescence ratio and the FAP ratio in the mouse and human STS cohorts (nhuman = 5, 
nmouse = 16). P value determined by F test on the linear regression model. (D) The [TP] in 
the tissue (in nM) was determined using the following equation: [LUM015]tissue + [fragment 
2]tissue + [fragment 3]tissue. [TP] data are shown for muscle and tumor tissue samples from 
human (n = 5, patients 8 and 11 to 14) and mouse (n = 18) STS subjects. P values 
determined by unpaired t test. (E and F) Tumor fluorescence versus [TP] in the mouse and 
human STS cohorts (nhuman = 5, nmouse = 16) (E) and in tumor and normal tissue samples 
from all human subjects (n = 14 per tissue type) (F). P values determined by F test on the 
linear regression models. (G) Tumor/muscle fluorescence ratios measured in mice 6 hours 
after injection with equimolar amounts of LUM015 or LUM033 (nLUM015 = 11, nLUM033 = 
9). P value determined by unpaired t test.
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Fig. 6. Visualizing tumor-selective LUM015 biodistribution
(A) PEG immunofluorescence of human tumor samples from LUM015-injected patients 
(+LUM015 representative image from patient 2) and from uninjected patients (−LUM015 
representative image from n = 3 patients) with UPS. (B) PEG immunofluorescence of 
margin tissue from LUM015-injected breast cancer patient 15. T, tumor tissue; N, normal 
breast tissue. The corresponding H&E histology is shown. (C) Immunohistochemistry for 
PEG in normal muscle tissue, normal breast tissue, and tumor tissue. Representative images 
of normal muscle and UPS (patient 2) as well as normal breast and IDC (patient 9). (D) 
Quantification of PEG staining intensity in tumors and normal tissues (n = 14 per tissue 
type; 1 tumor and 1 normal tissue sample from each patient except patient 10). P value 
determined by Mann-Whitney test.
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